🚀 VC round data is live in beta, check it out!
PureTech Health Valuation Multiples
Discover revenue and EBITDA valuation multiples for PureTech Health and similar public comparables like Ever Supreme Bio Technology, Opus Genetics, Newron Pharmaceuticals, Autolus Therapeutics and more.
PureTech Health Overview
About PureTech Health
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Founded
2015
HQ
Employees
56
Website
Sectors
Financials (FY)
EV
$89M
PureTech Health Financials
PureTech Health reported last fiscal year revenue of $5M and EBITDA of $37M.
In the same fiscal year, PureTech Health generated $37M in EBITDA and $54M in net income.
Revenue (LTM)
PureTech Health P&L
In the most recent fiscal year, PureTech Health reported revenue of $5M and EBITDA of $37M.
PureTech Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $5M | XXX | XXX | XXX |
| EBITDA | — | XXX | $37M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 774% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (2807%) | XXX | XXX | XXX |
| Net Profit | — | XXX | $54M | XXX | XXX | XXX |
| Net Margin | — | XXX | 1108% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PureTech Health Stock Performance
PureTech Health has current market cap of $390M, and enterprise value of $89M.
Market Cap Evolution
PureTech Health's stock price is $1.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $89M | $390M | 9.4% | XXX | XXX | XXX | $0.22 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPureTech Health Valuation Multiples
PureTech Health trades at 18.5x EV/Revenue multiple, and 2.4x EV/EBITDA.
EV / Revenue (LTM)
PureTech Health Financial Valuation Multiples
As of April 10, 2026, PureTech Health has market cap of $390M and EV of $89M.
Equity research analysts estimate PureTech Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PureTech Health has a P/E ratio of 7.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $390M | XXX | $390M | XXX | XXX | XXX |
| EV (current) | $89M | XXX | $89M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 18.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (0.7x) | XXX | XXX | XXX |
| P/E | — | XXX | 7.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PureTech Health Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PureTech Health Margins & Growth Rates
PureTech Health's revenue in the last fiscal year grew by 475%.
PureTech Health's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $2.5M for the same period.
PureTech Health Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 475% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 774% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (311%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 569% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1635% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 2908% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PureTech Health Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ever Supreme Bio Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| Opus Genetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Newron Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Autolus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Formycon | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PureTech Health M&A Activity
PureTech Health acquired XXX companies to date.
Last acquisition by PureTech Health was on XXXXXXXX, XXXXX. PureTech Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PureTech Health
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPureTech Health Investment Activity
PureTech Health invested in XXX companies to date.
PureTech Health made its latest investment on XXXXXXXX, XXXXX. PureTech Health invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PureTech Health
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PureTech Health
| When was PureTech Health founded? | PureTech Health was founded in 2015. |
| Where is PureTech Health headquartered? | PureTech Health is headquartered in United States. |
| How many employees does PureTech Health have? | As of today, PureTech Health has over 56 employees. |
| Who is the CEO of PureTech Health? | PureTech Health's CEO is Bharatt M. Chowrira. |
| Is PureTech Health publicly listed? | Yes, PureTech Health is a public company listed on London Stock Exchange. |
| What is the stock symbol of PureTech Health? | PureTech Health trades under PRTC ticker. |
| When did PureTech Health go public? | PureTech Health went public in 2015. |
| Who are competitors of PureTech Health? | PureTech Health main competitors are Ever Supreme Bio Technology, Opus Genetics, Newron Pharmaceuticals, Autolus Therapeutics. |
| What is the current market cap of PureTech Health? | PureTech Health's current market cap is $390M. |
| What is the current revenue of PureTech Health? | PureTech Health's last fiscal year revenue is $5M. |
| What is the current EV/Revenue multiple of PureTech Health? | Current revenue multiple of PureTech Health is 18.5x. |
| Is PureTech Health profitable? | No, PureTech Health is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.